s-14

TF-S14 is an inverse agonist of RORγt. It functions by binding to RORγt and inhibiting its activity, leading to a reduction in Th17 cell-associated cytokine production, including IL-17A, IL-21, and IL-22. TF-S14 is applicable in research related to autoimmune diseases and allogeneic transplant rejection.

GNS-1481 is a novel EGFR kinase inhibitor specifically targeting the T790M mutant variant of EGFR.

WMS-1405 is a derivative of ifenprodil. As a potent NR2B-selective NMDA receptor antagonist, it exhibits a Ki value of 5.4 nM. Synthesized through a central building block approach, WMS-1405 displays high NR2B affinity due to the specific distance between its basic nitrogen atom and phenyl residue. WMS-1405 has the potential to serve as an NMDA antagonist for excitotoxicity treatment.

GS-1427 (Emvistegrast) is a quinolone derivative and integrin α4β7 antagonist for studying α4β7 integrin-mediated diseases such as inflammatory bowel disease (IBD).

MRS-1477 is used as a TRPV1 positive allosteric modulator (PAM).

S-14671 is a 5-HT1A receptor agonist (pKi = 9.3) with high efficacy and exceptional in vivo potency. S-14671 also acts as a 5-HT2A and 5-HT2C receptor antagonist (both are pKi = 7.8).

UNBS-1450 is a sodium channel antagonist. UNBS-1450 is a hemi-synthetic cardenolide derived from 2″-oxovorusharin, it is effective against various cancer cell types with an excellent differential toxicity. At low nanomolar concentrations, UNBS-1450 induce

IS-145 is a thromboxane A2 receptor antagonist.

GBS-149 is a novel non-toxic and mammalian-specific LINE-1 inhibitor.

Inobrodib (CBP-IN-1) is a potent inhibitor of p300/CBP bromodomain.

Praeruptorin B (Praeruptorin D), a compound found in the roots of Peuced, is an inhibitor of sterol regulatory element-binding proteins (SREBPs) that attenuates the metastatic ability of human renal cancer cells by targeting CTSC and CTSV expression, and can be used in the study of osteoporosis.

Fenclozine Maleate (S 1429) is a potential histamine H1 receptor antagonist , which can be used to study fever, inflammation and pain.

Benazepril hydrochloride (CGS 14824A HCl) is an angiotensin-converting enzyme (ACE) inhibitor widely used in the therapy of hypertension. Benazepril hydrochloride is associated with a low rate of transient serum aminotransferase elevations and has been linked to rare instances of acute liver injury.

S 14506 hydrochloride is a 5-HT1A receptor full agonist.

(2S,3S)-Pterosin S 14-O-glucoside is a useful organic compound for research related to life sciences and the catalog number is T124536.

PDE7 inhibitor S14 is a cell-permeable PDE7 inhibitor that acts by targeting the cyclic adenosine monophosphate (cAMP)/cAMP-response element-binding protein (CREB) pathway.

cIAP1 Ligand-Linker Conjugates 14 consist of an IAP ligand that targets the E3 ubiquitin ligase and a PROTAC linker. These conjugates, known as cIAP1 Ligand-Linker Conjugates 14, are used in the development of SNIPERs[1].

Pomalidomide-C2-amido-(C1-O-C5-O-C1)2-COOH is a chemically synthesized E3 ligase ligand-linker conjugate, incorporating the cereblon ligand from Pomalidomide and a linker used in PROTAC technology. It facilitates targeted protein degradation by modulating E3 ligase activity, thereby enabling the selective elimination of specific proteins of interest.

Thalidomide-O-amido-PEG3-C2-NH2 (Cereblon Ligand-Linker Conjugates 3) is an E3 ligase ligand-linker conjugate developed using a Thalidomide-based cereblon ligand and a 3-unit PEG linker, synthesized specifically for use in PROTAC technology.

VH032-thiol-C6-NH2, also known as VHL Ligand-Linker Conjugates 14, is a synthesized compound that functions as an E3 ligase ligand-linker conjugate. This compound combines the VH032 based VHL ligand with a linker commonly utilized in PROTAC technology.

Benazeprilat(CGS 14831) is an orally active active metabolite of Benazepril.Benazeprilat has potent antihypertensive activity and can be used in combination with other classes of compounds, including thiazide diuretics and calcium channel blockers, to reduce the incidence of diseases associated with cardiovascular risk and secondary end-organ damage.Benazeprilat may be be used to study acute left ventricular failure.

RS14203, an orally active inhibitor of type IV cyclic nucleotide phosphodiesterase (PDE IV), has the capability to induce emesis.

AS1411-C4-VH032 (AS1411-VH032) selectively promotes the degradation of MDM2, leading to tumor shrinkage without detectable toxicity.

Lazertinib (mesylate) (YH25448 (mesylate); GNS-1480 (mesylate)) is an orally active EGFR inhibitor capable of crossing the blood-brain barrier. It suppresses the p-EGFR, p-AKT, and p-ERK signaling pathways, leading to apoptosis. Lazertinib (mesylate) demonstrates antitumor activity in the H1975-luc BM xenograft model in mice and is applicable for researching non-small cell lung cancer.